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ABPM constitutes a valuable tool in the diagnosis of RH. The identiﬁcation of white coat RH and masked hypertension (which
may fulﬁll or not the deﬁnition of RH) is of great importance in the clinical management of such patients. Moreover, the various
ABPM components such as average BP values, circadian BP variability patterns, and ambulatory BP-derived indices, such as
ambulatory arterial stiﬀness index (AASI), add signiﬁcantly to the risk stratiﬁcation of RH. Lastly, ABPM may indicate the need
for implementation of speciﬁc therapeutic strategies, such as chronotherapy, that is, administration-time dependent therapy, and
the evaluation of their eﬃcacy.
1.Introduction
Ambulatory blood pressure monitoring (ABPM) is the
method of obtaining automated brachial blood pressure
(BP) measurements at ﬁxed time intervals, during a 24-hour
period away from a medical environment. This represents a
more “realistic” approach to BP assessment since it involves
BP measurement during the usual daily activities and sleep.
In this sense, the overall haemodynamic load and BP
variability is more accurately estimated. Numerous studies
have shown that ambulatory BP compared to oﬃce BP is
more reproducible and superior in predicting target organ
damage and incidence of cardiovascular events in both the
generalhypertensivepopulation andinsubjectswithchronic
kidney disease [1, 2]. All these advantages of ambulatory BP
in comparison to oﬃce BP, along with the ability to identify
the white coat phenomenon, that is, the combination of
increased oﬃce BP with normal ambulatory BP, and masked
hypertension, that is, the combination of normal oﬃce BP
with increased ambulatory BP, resulted in the transition of
ABPM from a research tool to a clinical modality.
The indications for ABPM in the clinical management
of hypertensives include among others the resistance to
treatment[3]. This has been deﬁned asBP above goaldespite
the use of three agents of diﬀerent classes in optimal doses,
ideally including a diuretic. More recently hypertension
controlled with four or more agents has been proposed
to be included in the spectrum of resistant hypertension
[4]. Although the prognosis of resistant hypertension (RH)
is inadequately substantiated in the literature due to lack
of suﬃciently powered studies, there is plenty of evidence
relating target organ damage and cardiovascular outcomes
to BP levels. Uncontrolled BP along with a clustering of
other risk factors is a harbinger of poor outcome in RH.
Consequently, ABPM has implications in both the diagnosis
and management of RH.
2. ABPM As a Tool for the Diagnosis of
Resistant Hypertension
One of the crucial points in the identiﬁcation of RH as
a unique hypertension-related phenomenon that warrants
special management is the distinction of true RH from
“pseudoresistance” [3]. The latter term is used to describe
clinical situations with increased BP readings because of2 International Journal of Hypertension
improper BP measurement technique, heavily calciﬁed
arteries, white coat eﬀect, and lack of compliance to the
prescribed medication. White coat RH, a phenomenon that
is characterized by elevated oﬃce BP but normal ambulatory
andhomeBP[2]rangesfrom25toover50%insubjectswith
apparent resistance to treatment [5–7].
Muxfeldt et al., in a cohort of 286 hypertensive
subjects with uncontrolled BP, found that 43.7% had
white coat RH, (oﬃce BP > 140/90mmHg and daytime
BP < 135/85mmHg) and less target organ damage com-
pared to the true resistant hypertensives [6]. In support,
Pierdomenico et al. [7] in a cohort of 742 treated hyperten-
sive subjects, 426 apparently responders and 276 apparently
resistant, found that 126 subjects (29.5% of the apparently
responders) had masked hypertension and 146 (52.8% of
the apparent resistant) had white coat RH. In the same
study, in the follow-up period cardiovascular risk was higher
in masked hypertensives (masked versus responder hyper-
tensives, relative risk (RR) 2.28, 95% conﬁdence interval
(CI) 1.1–4.7, P<. 05) and in true resistant hypertensives
(true resistant versus responder hypertensives, RR 2.94, 95%
CI 1.02–8.41, P<. 05) [7]. According to the above, a
signiﬁcant proportion of treated subjects with apparently
controlled hypertension may actually “mask” their poor
response to treatment and some of them could possibly be
classiﬁed as subjects with resistant hypertension. Therefore,
ABPM identiﬁes patients with white coat RH or masked
hypertension contributing to avoiding overtreatment in the
ﬁrst case and achieving optimal management in the second
one.
Regarding BP measurement at home and at the oﬃce,
the established guidelines are not always followed resulting
in false BP readings [8]. This cause of pseudoresistance could
be identiﬁed with ABPM usage.
Consequently,thephysicianhavingconﬁrmedtheadher-
ence to the prescribed therapy that includes three antihy-
pertensive agents at full doses, including a diuretic, should
use ABPM in order to label the patient as truly resistant
hypertensive [9].
3.ABPM Characteristicsof
ResistantHypertensives
Since ABPM is a fundamental tool to diﬀerentiate true
RH from white-coat RH, it has been widely used in the
identiﬁcation of the BP pattern that characterizes patients
with RH. Muxfeldt et al. demonstrated that subjects with
true RH compared to white coat RH had lower nocturnal
systolic BP reductions (6.4 ± 8.8 versus 9.8 ± 7.5mmHg,
P = .0004), lower nocturnal diastolic BP (10.4 ± 9.6 versus
13.6 ± 9.2mmHg, P = .001), and a higher percentage of
nondippers (i.e., subjects nighttime BP fall <10% of the
corresponding daytime BP values) (68.7% versus 49.6%, P =
.001) [6]. Similarly Friedman and Logan showed that the
prevalence of nondipping among normotensive, controlled
hypertensive, and resistant hypertensive subjects was 25.0%,
42.3%, and 61.5%, respectively, (P = .006) [10]. It should
be emphasized that in terms of pathophysiology, both RH
and nondipping status have been linked to sympathetic over-
activity,subclinicalinﬂammation,andvolumeoverload[11–
14].Furthermore,thefailureoftheoncedailyadministration
of antihypertensive drugs to provide 24-hour coverage has
been identiﬁed as a cause of high nighttime BP, nondipping
pattern and true RH [15].
By deﬁnition, subjects with true RH compared to
those with white-coat eﬀect present signiﬁcantly higher
ambulatory BP. Apart from this, certain studies demonstrate
that patients with true RH have also increased ambulatory
pulse pressure in comparison with those with white coat
RH [6, 16]. Interestingly ambulatory 24-hour, daytime, and
nighttime heart rate is higher in true resistant hypertensives,
supporting the notion that increased sympathetic activation
may be present in true RH [16].
4.ABPM andCardiovascularPrognosisinRH
Although it is well known that the risk for cardiovascular
hard end points in hypertension disease rises as the BP levels
rise [17], there is a lack of evidence on the cardiovascular
prognosis of RH. There is one study demonstrating the
higher risk of patients with true RH compared to those with
white-coat RH for fatal and nonfatal cardiovascular events
[7]. On the other hand, there are studies evaluating the
prognostic role of ABPM and its indices in patients with
RH, highlighting its signiﬁcance in the clinical management.
In particular, Salles et al. in a cohort of 556 subjects with
resistanthypertensiondemonstratedthat24-hour(HR:1.32;
95% CI: 1.08–1.60; P<. 01), daytime (HR: 1.26; 95% CI:
1.04–1.53; P<. 005), and nighttime systolic BP (HR: 1.38;
95% CI: 1.13–1.68; P<. 01), 24-hour (HR: 1.33; 95% CI:
1.06–1.66; P<. 01), daytime (HR: 1.31; 95% CI: 1.05–
1.63; P<. 01), and nighttime (HR: 1.36; 95% CI: 1.10–
1.69; P<. 05) diastolic BP, and 24-hour (HR: 1.22; 95%
CI: 1.00–1.48; P<. 01) and nighttime (HR: 1.27; 95%
CI: 1.04–1.55; P<. 01) pulse pressure were independent
predictors of fatal and nonfatal cardiovascular events and of
cardiovascular and total mortality irrespectively of the oﬃce
BP values [18]. Of note, there was no diﬀerence between
systolic and diastolic BP, while pulse pressure was a weaker
predictor and nighttime BP was superior to daytime BP [18].
Similarly Redon et al. exhibited that in 86 subjects with
RH daytime diastolic BP predicted cardiovascular events
(lower tertile versus higher tertile of daytime diastolic BP;
RR: 6.42; 95% CI: 1.39–29.7; P = .017), while oﬃce BP had
no prognostic signiﬁcance [19].
Concerning the prognostic information of nondipping
pattern in RH, Muxfeldt et al. demonstrated that, in a
cohort of 556 subjects with RH, BP nondipping predicted
a composite end point of fatal and nonfatal cardiovascular
events, cardiovascular and total mortality (HR: 1.74; 95%
CI: 1.12–2.71, HR: 2.31; 95% CI: 1.09–4.92, HR: 1.67; 95%
CI: 0.95–2.94, resp.) above and beyond other traditional
cardiovascular risk factors and mean ambulatory BP levels
[20]. However, these results were not conﬁrmed in other
studies [21].
Although there are scarce data on the comparative
value of the aforementioned indices derived from ABPM asInternational Journal of Hypertension 3
potential prognostic markers in RH, in a study of Magnanini
et al. in women with RH, uncontrolled daytime BP was
the stronger independent risk factor (RR: 1.67; 95% CI
1.00–2.78) [21].
Adding to the cluster of components of ABPM that
carry valuable prognostic information, ambulatory arterial
stiﬀness index (AASI), which has been deﬁned as the
regression slope of diastolic on systolic BP [22], emerges
as a potential predictor of cardiovascular morbidity and
mortality in RH (HR: 1.46; 95% CI: 1.12–1.92), after
adjustment for traditional risk factors and other ABPM
parameters [23].
5. Association of ABPM Components with
TargetOrganDamageinRH
ABPM can be useful as the components derived from it
have been associated with target organ damage surrogates
in hypertension. More speciﬁcally, high-pulse pressure and
nondipping status in resistant hypertensives have been
associated with a high-cardiovascular risk proﬁle including
greater age, higher prevalence of cerebrovascular disease and
nephropathy,increasedserumcreatinineandmicroalbumin-
uria, and higher left ventricular mass index [24]. Moreover, a
b l u n t e dn o c t u r n a lr e d u c t i o ni nB P ,aw i d e n e d2 4 - h o u rp u l s e
pressure and AASI have been independently associated with
increased aortic stiﬀness in resistant hypertensive patients
[21, 24]. Finally, according to some studies 24-hour pulse
pressure presents a closer correlation to target organ damage
compared to the other ABPM indices [23, 25].
6. ABPM Implications in the RH Treatment
A B P Me m e r g e sn o w a d a y sa sau s e f u lt o o li nt h ee v a l u a t i o n
of the eﬃcacy of antihypertensive treatment in clinical
trials [26]. The conrtibution of ABPM in the assessment
of treatment eﬀectiveness, could be more prominent in the
setting of RH, where it has been shown to possess a pivotal
role in haemodynamic load evaluation [27]. Additionally,
apart from just testing the eﬃcacy of diﬀerent drugs, ABPM
has been used in the evaluation of the implementation of
certain therapeutic strategies in resistant hypertensives by
evaluating patients’ compliance [28].
Furthermore, as ABPM reveals the unfavorable circadian
BP pattern of patients with RH, namely, the nondipping
proﬁle, APBM has been used in the investigation of the
eﬃcacy of therapeutic strategies aiming at administration-
time-dependent eﬀects (chronotherapy) on the circadian BP
pattern and on the degree of 24-hour BP control in RH
[29]. Because a possible cause of the unfavorable BP pattern
in RH is the short-acting antihypertensive treatment that is
based on a single morning dosage, administration of one
of the three drugs at bedtime may result in better clinic
and ambulatory BP control as well as in lower prevalence of
nondipping pattern [30, 31].
Some of the disadvantages of ABPM such as cuﬀ
discomfort or procedure-related disturbed sleep may be
overcome with the use of home BP as a means of out of
oﬃce assessment of BP. However, evidence of the superiority
of home BP over oﬃce BP, for the assessment of RH, is scarce
while there are no data regarding any comparisons with
ABPM, which for the present represents the most reliable
tool in this setting.
References
[1] T. G. Pickering, D. Shimbo, and D. Haas, “Ambulatory blood-
pressure monitoring,” The New England Journal of Medicine,
vol. 354, no. 22, pp. 2316–2374, 2006.
[2] V. Pogue, M. Rahman, M. Lipkowitz et al., “Disparate
estimates of hypertension control from ambulatory and clinic
blood pressure measurements in hypertensive kidney disease,”
Hypertension, vol. 53, no. 1, pp. 20–27, 2009.
[3] P. A. Saraﬁdis and G. L. Bakris, “Resistant hypertension. An
overviewofevaluationandtreatment,”JournaloftheAmerican
College of Cardiology, vol. 52, no. 22, pp. 1749–1757, 2008.
[4] D. A. Calhoun, D. Jones, S. Textor et al., “Resistant hyper-
tension: siagnosis, evaluation, and treatment a scientiﬁc
statement from the american heart association professional
education committee of the council for high blood pressure
research,” Hypertension, vol. 51, no. 6, pp. 1403–1419, 2008.
[5] M.A.Brown,M.L.Buddle,andA.Martin,“Isresistanthyper-
tension really resistant?” American Journal of Hypertension,
vol. 14, no. 12, pp. 1263–1269, 2001.
[6] E. S. Muxfeldt, K. V. Bloch, A. R. Nogueira, and G. F. Salles,
“Twenty-four hour ambulatory blood pressure monitoring
pattern of resistant hypertension,” Blood Pressure Monitoring,
vol. 8, no. 5, pp. 181–185, 2003.
[7] S. D. Pierdomenico, D. Lapenna, A. Bucci et al., “Cardiovascu-
lar outcome in treated hypertensive patients with responder,
masked, false resistant, and true resistant hypertension,”
American Journal of Hypertension, vol. 18, no. 11, pp. 1422–
1428, 2005.
[8] S. W. Tobe and R. Lewanczuk, “Resistant hypertension,” The
Canadian Journal of Cardiology, vol. 25, no. 5, pp. 315–317,
2009.
[9] W. B. White, “Ambulatory blood pressure monitoring as an
investigative tool for characterizing resistant hypertension and
its rational treatment,” Journal of Clinical Hypertension, vol. 9,
supplement 1, pp. 25–30, 2007.
[10] O. Friedman and A. G. Logan, “Nocturnal blood pressure
proﬁles among normotensive, controlled hypertensive and
refractory hypertensive subjects,” The Canadian Journal of
Cardiology, vol. 25, no. 9, pp. e312–e316, 2009.
[11] F. Sayk, C. Becker, C. Teckentrup et al., “To dip or not to dip:
onthephysiologyofbloodpressuredecreaseduringnocturnal
sleep in healthy humans,” Hypertension,v o l .4 9 ,n o .5 ,p p .
1070–1076, 2007.
[12] J.W.Graves,R.L.Bloomﬁeld,andV.M.BuckalewJr.,“Plasma
volume in resistant hypertension: guide to pathophysiology
andtherapy,”TheAmericanJournaloftheMedicalSciences,vol.
298, no. 6, pp. 361–365, 1989.
[13] T. Uzu, K. Ishikawa, T. Fujii, S. Nakamura, T. Inenaga, and G.
Kimura, “Sodium restriction shifts circadian rhythm of blood
pressure from nondipper to dipper in essential hypertension,”
Circulation, vol. 96, no. 6, pp. 1859–1862, 1997.
[14] C. Tsiouﬁs, D. Syrseloudis, K. Dimitriadis et al., “Disturbed
circadian blood pressure rhythm and C-reactive protein in
essential hypertension,” J o u r n a lo fH u m a nH y p e r t e n s i o n , vol.
22, no. 7, pp. 501–508, 2008.4 International Journal of Hypertension
[ 1 5 ]R .C .H e r m i d a ,D .E .A y a l a ,C .C a l v oe ta l . ,“ E ﬀects of time
of day of treatment on ambulatory blood pressure pattern of
patients with resistant hypertension,” Hypertension., vol. 46,
no. 4, pp. 1053–1059, 2005.
[16] F. Veglio, F. Rabbia, P. Riva et al., “Ambulatory blood
pressuremonitoringandclinicalcharacteristicsofthetrueand
white-coat resistant hypertension,” Clinical and Experimental
Hypertension, vol. 23, no. 3, pp. 203–211, 2001.
[17] S. Lewington, R. Clarke, N. Qizilbash, R. Peto, and R. Collins,
“Age-speciﬁc relevance of usual blood pressure to vascular
mortality: a meta-analysis of individual data for one million
adults in 61 prospective studies,” The Lancet, vol. 360, no.
9349, pp. 1903–1913, 2002.
[18] G. F. Salles, C. R. L. Cardoso, and E. S. Muxfeldt, “Prognostic
inﬂuence of oﬃce and ambulatory blood pressures in resistant
hypertension,” Archives of Internal Medicine, vol. 168, no. 21,
pp. 2340–2346, 2008.
[19] J .Redon,C.Campos,M.L.N arciso ,J .L.Rodicio ,J .M.P ascual,
and L. M. Ruilope, “Prognostic value of ambulatory blood
pressure monitoring in refractory hypertension: a prospective
study,” Hypertension, vol. 31, no. 2, pp. 712–718, 1998.
[20] E. S. Muxfeldt, C. R. L. Cardoso, and G. F. Salles, “Prognostic
value of nocturnal blood pressure reduction in resistant
hypertension,” Archives of Internal Medicine, vol. 169, no. 9,
pp. 874–880, 2009.
[21] M. M. F. Magnanini, A. D. R. Nogueira, M. S. Carvalho,
and K. V. Bloch, “Ambulatory blood pressure monitoring and
cardiovascular risk in resistant hypertensive women,” Arquivos
Brasileiros de Cardiologia, vol. 92, no. 6, pp. 448–489, 2009.
[22] E. Dolan, L. Thijs, Y. Li et al., “Ambulatory arterial stiﬀness
index as a predictor of cardiovascular mortality in the dublin
outcome study,” Hypertension, vol. 47, no. 3, pp. 365–370,
2006.
[ 2 3 ]E .S .M u x f e l d t ,C .R .L .C a r d o s o ,V .B .D i a s ,A .C .M .
Nascimento, and G. F. Salles, “Prognostic impact of the
ambulatory arterial stiﬀness index in resistant hypertension,”
Journal of Hypertension, vol. 28, no. 7, pp. 1547–1553, 2010.
[24] C. H. Castelpoggi, V. S. Pereira, R. Fiszman, C. R. L. Cardoso,
E. S. Muxfeldt, and G. F. Salles, “A blunted decrease in
nocturnal blood pressure is independently associated with
increased aortic stiﬀness in patients with resistant hyperten-
sion,” Hypertension Research, vol. 32, no. 7, pp. 591–596, 2009.
[25] E. S. Muxfeldt and G. F. Salles, “Pulse pressure or dipping
pattern: which one is a better cardiovascular risk marker in
resistant hypertension?” Journal of Hypertension, vol. 26, no.
5, pp. 878–884, 2008.
[26] A. J. S. Coats, “Beneﬁts of ambulatory blood pressure mon-
itoring in the design of antihypertensive drug trials,” Blood
Pressure Monitoring, vol. 1, no. 2, pp. 157–160, 1996.
[ 2 7 ] A .D e e s ,T .K .K .H o v i n g a ,J .G .S .B r e e d ,V .M .C .V e r s t a p p e n ,
S. M. T. Puister, and L. Meems, “Calcium antagonists, a
useful additional therapy in treatment resistant hypertension:
comparison of felodipine ER and nifedipine Retard by 24-h
ambulatory blood pressure monitoring,” Netherlands Journal
of Medicine, vol. 50, no. 1, pp. 2–12, 1997.
[28] M.S.d eC astr o ,F .D .F uc hs,M.C.Sant osetal.,“Pharmac e u ti-
cal care program for patients with uncontrolled hypertension.
Report of a double-blind clinical trial with ambulatory blood
pressure monitoring,” American Journal of Hypertension, vol.
19, no. 5, pp. 528–533, 2006.
[ 2 9 ]R .C .H e r m i d a ,D .E .A y a l a ,C .C a l v oe ta l . ,“ E ﬀects of time
of day of treatment on ambulatory blood pressure pattern of
patients with resistant hypertension,” Hypertension., vol. 46,
no. 4, pp. 1053–1059, 2005.
[ 3 0 ]R .C .H e r m i d a ,D .E .A y a l a ,J .R .F e r n ´ andez, and C. Calvo,
“Chronotherapy improves blood pressure control and reverts
thenondipperpatterninpatientswithresistanthypertension,”
Hypertension, vol. 51, no. 1, pp. 69–76, 2008.
[ 3 1 ]R .C .H e r m i d a ,D .E .A y a l a ,A .M o j ´ on, and J. R. Fern´ andez,
“Eﬀects of time of antihypertensive treatment on ambulatory
blood pressure and clinical characteristics of subjects with
resistant hypertension,” American Journal of Hypertension, vol.
23, no. 4, pp. 432–439, 2010.